<html xmlns="http://www.w3.org/1999/xhtml" lang="en-US"><head><meta charset="UTF-8"><meta http-equiv='content-language' content='en-us'/><title>SDLRC - Codified Law 34-20B-14 - Hallucinogenic substances included in Schedule I.</title><meta name="Generator" content="PowerTools for Open XML"><style>span { white-space: pre-wrap; } p.s6ed24474973d4c0693f479b4af6cd23bNormal { text-indent: 0.50in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-left: 0; margin-right: 0; margin-bottom: .001pt; } span.s6ed24474973d4c0693f479b4af6cd23bSENU { font-family: 'Times New Roman', 'serif'; font-size: 12pt; font-style: normal; font-weight: bold; margin: 0; padding: 0; } span.s6ed24474973d4c0693f479b4af6cd23bCL { font-family: 'Times New Roman', 'serif'; font-size: 12pt; font-style: normal; font-weight: bold; margin: 0; padding: 0; } p.s6ed24474973d4c0693f479b4af6cd23bStatute { text-indent: 0.50in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-left: 0; margin-right: 0; margin-bottom: .001pt; } span.s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont { font-family: 'Times New Roman', 'serif'; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; } p.s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1 { margin-left: 0.75in; text-indent: -0.45in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-right: 0; margin-bottom: .001pt; } p.s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2 { margin-left: 1.25in; text-indent: -0.44in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-right: 0; margin-bottom: .001pt; } p.s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000000 { margin-left: 0.75in; text-indent: -0.50in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-right: 0; margin-bottom: .001pt; } p.s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001 { margin-left: 1.25in; text-indent: -0.50in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-right: 0; margin-bottom: .001pt; } p.s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000002 { margin-left: 0.75in; text-indent: -0.44in; text-align: justify; background: #FFFFFF; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-right: 0; margin-bottom: .001pt; } span.s6ed24474973d4c0693f479b4af6cd23b000003 { font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; } p.s6ed24474973d4c0693f479b4af6cd23bNoIndent { text-indent: 0.00in; text-align: justify; font-family: 'Times New Roman', 'serif'; font-size: 12pt; line-height: 108%; margin-top: 0; margin-left: 0; margin-right: 0; margin-bottom: .001pt; } span.s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont-000004 { font-family: 'Times New Roman', 'serif'; font-size: 12pt; font-style: normal; font-weight: bold; margin: 0; padding: 0; } span.s6ed24474973d4c0693f479b4af6cd23bSCL { font-family: 'Times New Roman', 'serif'; font-size: 12pt; font-style: normal; font-weight: normal; margin: 0; padding: 0; } body { text-decoration-skip-ink: none; } </style><meta name="viewport" content="width=device-width, initial-scale=1"><meta name="twitter:card" content="summary"><meta property="og:title" content="SD 34-20B-14 - Hallucinogenic substances included in Schedule I."><meta property="og:description" content="SDLRC Codified Law 34-20B-14 - Hallucinogenic substances included in Schedule I."><meta property="og:type" content="website"><meta property="og:url" content="https://sdlegislature.gov/Statutes/34-20B-14"><meta property="og:image" content="https://lawmakerdocuments.blob.core.usgovcloudapi.net/photos/logoshape.webp"><meta property="og:site_name" content="South Dakota Legislature"></head><body><div><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bNormal"><a href="https://sdlegislature.gov/Statutes?Statute=34-20B-14" rel="noopener"><span class="s6ed24474973d4c0693f479b4af6cd23bSENU">34-20B-14</span></a><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bSENU">. </span><span class="s6ed24474973d4c0693f479b4af6cd23bCL">Hallucinogenic substances included in Schedule I.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatute"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(1)Bufotenine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(2)Diethyltryptamine (DET);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(3)Dimethyltryptamine (DMT);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(4)5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(5)5-methoxy-3, 4-methylenedioxy amphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(6)4-bromo-2, 5-dimethoxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(7)4-methoxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(8)4-methoxymethamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(9)4-methyl-2, 5-dimethoxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(10)Hashish and hash oil;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(11)Ibogaine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(12)Lysergic acid diethylamide;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(13)Mescaline;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(14)N-ethyl-3-piperidyl benzilate;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(15)N-methyl-3-piperidyl benzilate;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(16)1-(-(2-thienyl)cyclohexyl) piperidine (TCP);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(17)Peyote, except that when used as a sacramental in services of the Native American church in a natural state which is unaltered except for drying or curing and cutting or slicing, it is hereby excepted;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(18)Psilocybin;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(19)Psilocyn;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(20)Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in </span><a href="https://sdlegislature.gov/Statutes?Statute=38-35-1" rel="noopener"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">38-35-1</span></a><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">; in a drug product approved by the United States Food and Drug Administration; or marijuana in its natural and unaltered state; including any compound, except nabilone or compounds listed under a different schedule, structurally derived from 6,6 dimethyl-benzo[c]chromene by substitution at the 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, whether or not the compound is further modified in any of the following ways:</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(a)By partial to complete saturation of the C-ring; or</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(b)By substitution at the 1-position with a hydroxyl or methoxy group; or</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(c)By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl group; or</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(d)By modification of the possible 3-alkyl group with a 1,1 dimethyl moiety, a 1,1 cyclic moiety, an internal methylene group, an internal acetylene group, or a terminal halide, cyano, azido, or dimethylcarboxamido group.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000000"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM-087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; HU-336;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(21)3, 4, 5-trimethoxy amphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(22)3, 4-methylenedioxy amphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(23)3-methoxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(24)2, 5-dimethoxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(25)2-methoxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(26)2-methoxymethamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(27)3-methoxymethamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(28)Phencyclidine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(29)3, 4-methylenedioxymethamphetamine (MDMA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(30)3, 4-methylenedioxy-N-ethylamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(31)N-hydroxy-3, 4-methylenedioxyamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(32)4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(33)2,5 Dimethoxy-4-ethylamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(34)N,N-Dimethylamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(35)1-(1-(2-thienyl)cyclohexyl)pyrrolidine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(36)Aminorex;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(37)4,42 -Dimethylaminorex (4,42 -DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(38)Cathinone and other variations, defined as any compound, material, mixture, preparation or other product unless listed in another schedule or an approved FDA drug, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(a)By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substitutents;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(b)By substitution at the 3-position with an acyclic alkyl substituent; or</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(c)By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic structure.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000000"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4-Methyl-alpha-pyrrolidinobutiophenone (MPBP); Methyl--pyrrolindinopropiophenone (MPPP); Methyl--pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-N-ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC); Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC); Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl-alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC); Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB); Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N-ethyl-N-Methylcathinone; N-ethylbuphedrone, 1-(1,3-benzodioxol-5-yl)2-(ethylamino)pentan-1-one (N-Ethylpentylone); 4'-Methyl-alpha-pyrrolidinopropiophenone (4-MEPPP, MPPP or MPPP); alpha-Pyrrolidinobutiophenone (-PBP); 1-(1,3-benzodioxol-5-yl)-2-(tert-butylamino)propan-1-one (Tertylone); 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)hexan-1-one (N-ethyl Hexylone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pntan-1-one (Pentylone); N-ethylhexedrone ( ethylaminohexanophenone); alpha-pyrrolidinohexanophenone (-PHP); 4-methyl-alpha-ethylaminopentiophenone (4-MEAP); 42 -methyl-alpha-pyrrolidinohexiophenone (MPHP); alpha-pyrrolidinoheptaphenone (PV8); 42 -chloro-alpha-pyrrolidinovalerophenone (4-chloro--PVP); Alpha-PIHP (4-methyl-1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(39)2,5-Dimethoxy-4-ethylamphetamine (DOET);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(40)Alpha-ethyltryptamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(41)4-Bromo-2,5-dimethoxy phenethylamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(42)2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(43)1-(3-trifluoromethylphenyl) piperazine (TFMPP);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(44)Alpha-methyltryptamine (AMT);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(45)5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(46)5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(47)Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed as a controlled substance in another schedule, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, modifications of the indole ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or propionaldehyde structure, and salts of isomers, homologues, and modifications, unless specifically excepted, whenever the existence of these salts, isomers, homologues, modifications, and salts of isomers, homologues, and modifications is possible within the specific chemical designation:</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(a)Naphthoylindoles. Any compound containing a 2-(1- naphthoyl)indole or 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009; JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079; JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182; JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262; JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; AM-1221; AM-1235; AM-2232, THJ-2201;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(b)Naphthylmethylindoles. Any compound containing a 1H-indol-2-yl-(1-naphthyl)methane or 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: JWH-175; JWH-184; JWH-185; JWH-192; JWH-194; JWH-195; JWH-196; JWH-197; JWH-199;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(c)Phenylacetylindoles. Any compound containing a 2-phenylacetylindole or 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: 1-cyc lohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-316; Cannabipiperidiethanone;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(d)Benzoylindoles. Any compound containing a 2-(benzoyl)indole or 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; AM-661; AM-2233; AM-1241;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(e)Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the pyrrole ring to any extent and whether or not substituted on the naphthyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: JWH-307; JWH-030; JWH-031; JWH-145; JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; JWH-370; JWH-371; JWH-373; JWH-392;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(f)Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indene ring to any extent and whether or not substituted on the naphthyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: JWH-171; JWH-176; JWH-220;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(g)Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not substituted on the cyclohexyl ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade or other names: 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(h)(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: HU-210;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(i)2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 2</span><a href="https://sdlegislature.gov/Statutes?Statute=12-2" rel="noopener"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">12-2</span></a><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(j)Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-acetyl indole structure substituted at the acetyl by replacement of the methyl group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde substituent whether or not further substituted on the tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted on the indole ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade and or names: (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144); (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11); (1-(2-morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole (AM-1248); 1-Pentyl-3-(1-adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(k)Substituted Carboxamide Indole. Any compound containing a 2-carboxamide indole or 3-carboxamide indole structure substituted at the nitrogen of the carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl, phenyl, or propionaldehyde substituent, whether or not further substituted on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted on the indole ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade and other names: JWH-018 adamantyl carboxamide; STS-135; MN-18; 5-Fluoro-MN-18, 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA) ; N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA); methyl (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (5F-ADB); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (AB-CHMINACA); 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN-CUMYL-BUTINACA); N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (ADB-CHMINACA or MAB-CHMINACA); methyl (2S)-2-[[1-[4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-FUBINACA); methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA); methyl (2S)-2-[[1-[4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3-methylbutanoate (AMB-FUBINACA); Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB); methyl 2-(1-(5-fluoropentyl-1Hindole-3-carboxamido)-3,3-dimethylbutaoate (5F-MDMB-PICA); methyl (S)-3,3-dimethyl-2-[(1-(pent-4-enlindazole-3-carbonyl)amino]butanoate (MDMB-4en-PINACA); methyl 2-(1-(4-fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate (4F-MDMB-BUTINACA); Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PINACA); Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate S(5F-MDMB-PICA); N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (FUB-APINACA); 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (5F-CUMYL-PINACA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(l)Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent whether or not further substituted on the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group whether or not further substituted on the indole ring to any extent.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2-000001"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade and other names: Naphthalen-1-yl 1-(5-fluoropntyl)-1H-indole-3-carboxylate (NM2201);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(48)6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(49)2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(50)2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(51)2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(52)2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(53)2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(54)2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(55)2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(56)2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(57)2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(58)Substituted phenethylamine. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from phenylethan-2-amine by substitution on the phenyl ring in any of the following ways: by substitution with a fused methylenedioxy, fused furan, or fused tetrahydrofuran ring system; by substitution with two alkoxy groups; by substitution with one alkoxy and either one fused furan, tetrahydrofuran, or tetrahydropyran ring system; by substitution with two fused ring systems from any combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems; whether or not the compound is further modified in any of the following ways:</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(a)By substitution on the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(b)By substitution on the 2-position by any alkyl groups; or</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber2"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(c)By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl, benzyl, methoxybenzyl, or hydroxybenzyl groups.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000000"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade and other names: 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T or 4-methylthio-2,5-dimethoxyphenethylamine); 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI or 2, 5-Dimethoxy-4-iodoamphetamine); 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or 2,5-Dimethoxy-4-bromoamphetamine); 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-B-NBOMe; 25B-NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-I-NBOMe; 25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline-NBOMe or 3,4,5-trimethoxy-(2-methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY); 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine (2C-B-butterFLY); -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe); 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY); -(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or 25I-NBOH); 5-(2-Aminoprpyl)benzofuran (5-APB); 6(2-Aminopropyl)benzofuran (6-APB); 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran (6-APDB); para-methoxymethamphetamine (PMMA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(59)Substituted tryptamines. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from 2-(1H-indol-3-yl)ethanamine by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure whether or not the compound is further substituted at the alpha-position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups.</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000000"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(60)Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(61)N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(62)1-(4-Fluorophenyl)piperazine (pFPP);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(63)1-(3-Chlorophenyl)piperazine (mCPP);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(64)1-(4-Methoxyphenyl)piperazine (pMeOPP);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(65)1,4-Dibenzylpiperazine (DBP);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(66)Isopentedrone;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(67)Fluoromethamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(68)Fluoroamphetamine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(69)Fluorococaine;</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(70)1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(71)1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(72)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(73)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5 Fluoro-AB-PINACA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(74)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(75)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADB-PINACA (ADBICA));</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(76)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA));</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(77)N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA);</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(78)N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-3-carboxamide (5-Fluoro-3,5-AB-PFUPPYCA); and</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bStatuteNumber1-000002"><span class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont">(79)2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine).</span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bNormal"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23b000003"> </span></p><p dir="ltr" class="s6ed24474973d4c0693f479b4af6cd23bNoIndent"><span xml:space="preserve" class="s6ed24474973d4c0693f479b4af6cd23bDefaultParagraphFont-000004">Source: </span><span class="s6ed24474973d4c0693f479b4af6cd23bSCL">SL 1970, ch 229, 8(a)(1); SDCL Supp, 39-17-57; SL 1973, ch 259; SL 1976, ch 158, 42-12, 42-13; SL 1977, ch 315, 3; SL 1979, ch 238, 1; SL 1987, ch 255, 2; SL 1988, ch 282, 2; SL 1989, ch 293, 2; SL 1990, ch 270, 1; SL 1993, ch 247, 1; SL 1994, ch 278, 2; SL 2003, ch 183, 2; SL 2004, ch 230, 1; SL 2011, ch 160, 1, eff. Feb. 24, 2011; SL 2012, ch 183, 1, eff. Feb. 23, 2012; SL 2013, ch 156, 4, eff. Mar. 6, 2013; SL 2014, ch 165, 1, eff. Feb. 10, 2014; SL 2015, ch 180, 1, eff. Feb. 18, 2015; SL 2019, ch 148, 3, eff. Feb. 19, 2019; SL 2020, ch 176, 24, eff. Mar. 27, 2020; SL 2021, ch 144, 3, eff. Feb. 17, 2021; SL 2022, ch 109, 2, eff. Feb. 9, 2022; SL 2023, ch 119, 2, eff. Feb. 9, 2023; SL 2025, ch 139, 2, eff. Feb. 18, 2025.</span></p></div></body></html>